HCPCS code J9326 — Telisotuzumab vedotin-tllv. Status: Active. Effective Jan 1, 2026. Source: CMS HCPCS Level II.

J9326

Active

Telisotuzumab vedotin-tllv

Injection, telisotuzumab vedotin-tllv, 1 mg

Category: Drugs
Section: J-codes: Drugs Administered Other Than Oral Method
Effective: Jan 1, 2026
Code type: alphanumeric
OPPS Status: G — Pass-through drugs and biologicals
OPPS APC: 0894

NDC Crosswalk

National Drug Codes (NDCs) mapped to this HCPCS code.

NDC Drug Name
00074-1044-01 Emrelis
00074-1055-01 Emrelis

Change History

Quarterly changes published by CMS. Revisions may affect the code description, coverage, or rate — review each quarter's changes before submitting claims.

  • New Code 2026-Q1
    Telisotuzumab vedotin-tllv